IBDEI1BH ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23325,2)
 ;;=^24355
 ;;^UTILITY(U,$J,358.3,23326,0)
 ;;=414.01^^125^1406^23
 ;;^UTILITY(U,$J,358.3,23326,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23326,1,4,0)
 ;;=4^414.01
 ;;^UTILITY(U,$J,358.3,23326,1,5,0)
 ;;=5^Coronary Artery Disease
 ;;^UTILITY(U,$J,358.3,23326,2)
 ;;=^303281
 ;;^UTILITY(U,$J,358.3,23327,0)
 ;;=311.^^125^1406^25
 ;;^UTILITY(U,$J,358.3,23327,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23327,1,4,0)
 ;;=4^311.
 ;;^UTILITY(U,$J,358.3,23327,1,5,0)
 ;;=5^Depression
 ;;^UTILITY(U,$J,358.3,23327,2)
 ;;=^35603
 ;;^UTILITY(U,$J,358.3,23328,0)
 ;;=250.01^^125^1406^26
 ;;^UTILITY(U,$J,358.3,23328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23328,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,23328,1,5,0)
 ;;=5^Diabetes, Type 1
 ;;^UTILITY(U,$J,358.3,23328,2)
 ;;=^331780
 ;;^UTILITY(U,$J,358.3,23329,0)
 ;;=250.00^^125^1406^27
 ;;^UTILITY(U,$J,358.3,23329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23329,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,23329,1,5,0)
 ;;=5^Diabetes, Type 2
 ;;^UTILITY(U,$J,358.3,23329,2)
 ;;=^331779
 ;;^UTILITY(U,$J,358.3,23330,0)
 ;;=305.90^^125^1406^29
 ;;^UTILITY(U,$J,358.3,23330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23330,1,4,0)
 ;;=4^305.90
 ;;^UTILITY(U,$J,358.3,23330,1,5,0)
 ;;=5^Drug Abuse-Unspec
 ;;^UTILITY(U,$J,358.3,23330,2)
 ;;=^268258
 ;;^UTILITY(U,$J,358.3,23331,0)
 ;;=305.93^^125^1406^28
 ;;^UTILITY(U,$J,358.3,23331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23331,1,4,0)
 ;;=4^305.93
 ;;^UTILITY(U,$J,358.3,23331,1,5,0)
 ;;=5^Drug Abuse-In Remission
 ;;^UTILITY(U,$J,358.3,23331,2)
 ;;=^268261
 ;;^UTILITY(U,$J,358.3,23332,0)
 ;;=796.2^^125^1406^33
 ;;^UTILITY(U,$J,358.3,23332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23332,1,4,0)
 ;;=4^796.2
 ;;^UTILITY(U,$J,358.3,23332,1,5,0)
 ;;=5^Elevated BP w/o HTN
 ;;^UTILITY(U,$J,358.3,23332,2)
 ;;=^273464
 ;;^UTILITY(U,$J,358.3,23333,0)
 ;;=607.84^^125^1406^35
 ;;^UTILITY(U,$J,358.3,23333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23333,1,4,0)
 ;;=4^607.84
 ;;^UTILITY(U,$J,358.3,23333,1,5,0)
 ;;=5^Erectile Dysfunction
 ;;^UTILITY(U,$J,358.3,23333,2)
 ;;=^270441
 ;;^UTILITY(U,$J,358.3,23334,0)
 ;;=530.81^^125^1406^36
 ;;^UTILITY(U,$J,358.3,23334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23334,1,4,0)
 ;;=4^530.81
 ;;^UTILITY(U,$J,358.3,23334,1,5,0)
 ;;=5^GERD
 ;;^UTILITY(U,$J,358.3,23334,2)
 ;;=^295749
 ;;^UTILITY(U,$J,358.3,23335,0)
 ;;=389.9^^125^1406^39
 ;;^UTILITY(U,$J,358.3,23335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23335,1,4,0)
 ;;=4^389.9
 ;;^UTILITY(U,$J,358.3,23335,1,5,0)
 ;;=5^Hearing Loss NOS
 ;;^UTILITY(U,$J,358.3,23335,2)
 ;;=^54552
 ;;^UTILITY(U,$J,358.3,23336,0)
 ;;=784.0^^125^1406^38
 ;;^UTILITY(U,$J,358.3,23336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23336,1,4,0)
 ;;=4^784.0
 ;;^UTILITY(U,$J,358.3,23336,1,5,0)
 ;;=5^Headaches
 ;;^UTILITY(U,$J,358.3,23336,2)
 ;;=^54133
 ;;^UTILITY(U,$J,358.3,23337,0)
 ;;=070.54^^125^1406^40
 ;;^UTILITY(U,$J,358.3,23337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23337,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,23337,1,5,0)
 ;;=5^Hepatitis C
 ;;^UTILITY(U,$J,358.3,23337,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,23338,0)
 ;;=272.4^^125^1406^41
 ;;^UTILITY(U,$J,358.3,23338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23338,1,4,0)
 ;;=4^272.4
 ;;^UTILITY(U,$J,358.3,23338,1,5,0)
 ;;=5^Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,23338,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,23339,0)
 ;;=272.2^^125^1406^42
 ;;^UTILITY(U,$J,358.3,23339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,23339,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,23339,1,5,0)
 ;;=5^Hyperlipidemia,Mixed
 ;;
 ;;$END ROU IBDEI1BH
